News Release

Abatacept, cenicriviroc, or infliximab for treatment of adults hospitalized with COVID-19 pneumonia


Peer-Reviewed Publication

JAMA Network

About The Study: This randomized clinical trial found that treatment with abatacept, cenicriviroc, or infliximab showed no significant difference of time to recovery compared with placebo for patients hospitalized with COVID-19 pneumonia.

Authors: William G. Powderly, M.D., of the Washington University School of Medicine in St. Louis, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.